Can measuring brain function help us choose an antidepressant? ↗
Contrasts fMRI-based response prediction with identifying an autoimmune treatment target.
Frontier Science · TOPIC v1
Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor
How can receptor-directed autoimmunity be identified among patients with similar symptoms?
Read article → Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor
2026-09-29 15:11:40.000 UTC · Last recorded update
CURRENT READING
Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
Recorded editorial state, not a maturity score
- Reports and agreements reviewedRecorded
- Further validationUnverified
- Adoption and benefitUnverified
New question opened · v1
Recorded a new question and follow-up checks from the approved manuscript.
Permanent link to this revision ↗01 / WHAT WE TRACK
How can receptor-directed autoimmunity be identified among patients with similar symptoms?
02 / EVIDENCE & TECHNOLOGY
NMDA receptor / autoantibodies / monovalent antibody
03 / EDITORIAL READING
Receptor location and the cause of its disruption can inform treatment design, beyond expression alone.
04 / WHAT REMAINS UNKNOWN
Culture washout is not selective antibody removal in patients; preclinical improvements do not establish clinical efficacy.
05 / NEXT CHECK
Patient selection, CSF-inclusive assessment, and ART5803 safety and clinical outcomes.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDSeparating causes within symptom-defined groups may identify patients who can benefit from a different treatment.
What would change our view: Reconsider if receptor protection fails to improve symptoms, or the target group cannot be identified reproducibly.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTUREArialys ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTUREART5803 ↗
Mentioned in this issue
Related questions, optional follows
Map ↗Latest card updates
Latest 5 · editorial record dates- v1 · 2026-09-29 15:11:40.000 UTCNew question opened
Recorded a new question and follow-up checks from the approved manuscript.
Reading at the time: Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Background readings
Source dates and verification scope
臨床研究 ↗
pmc.ncbi.nlm.nih.gov · recorded 2026-09-29 · linked-primary-source
基礎研究 ↗
pmc.ncbi.nlm.nih.gov · recorded 2026-09-29 · linked-primary-source
前臨床研究 ↗
www.nature.com · recorded 2026-09-29 · linked-primary-source
臨床開発の発表 ↗
arialysrx.com · recorded 2026-09-29 · linked-primary-source